Bloonics
LumaCell is transforming diagnostics by developing AI-powered biosensor assays, offering bespoke, cost-effective solutions. Their technology centers on GPCR-based diagnostics, leveraging AI and Machine Learning for custom sensor design and data interpretation. LumaCell differentiates itself by optimizing hardware for improved data input quality, ensuring reliable insights. Their initial application focuses on detecting active THC impairment, aligning with evolving drug impairment laws. Future plans include developing at-home panels for monitoring GLP-1 agonists and cannabinoids to manage chronic diseases like Type 2 diabetes and chronic pain. The company aims to become a major player in GPCR-targeting pharmaceuticals, a sector representing over a third of the global drug market. Their platform utilizes genetically modified yeast cells for easy, adaptable, and cost-efficient production of biosensors.
Bloonics
LumaCell is transforming diagnostics by developing AI-powered biosensor assays, offering bespoke, cost-effective solutions. Their technology centers on GPCR-based diagnostics, leveraging AI and Machine Learning for custom sensor design and data interpretation. LumaCell differentiates itself by optimizing hardware for improved data input quality, ensuring reliable insights. Their initial application focuses on detecting active THC impairment, aligning with evolving drug impairment laws. Future plans include developing at-home panels for monitoring GLP-1 agonists and cannabinoids to manage chronic diseases like Type 2 diabetes and chronic pain. The company aims to become a major player in GPCR-targeting pharmaceuticals, a sector representing over a third of the global drug market. Their platform utilizes genetically modified yeast cells for easy, adaptable, and cost-efficient production of biosensors.